Rohto Pharmaceutical Co (JP:4527) has released an update.
Rohto Pharmaceutical Co., Ltd. reports a significant increase in sales and profits for the first quarter of FY3/2025, driven by the economic rebound post-pandemic and strong product demand, including popular items like ‘Melano CC’ and ‘Hadalabo’. Despite higher sales costs and planned increases in administrative expenses, operating and ordinary profits rose, although net income was impacted by extraordinary losses. Additionally, the company has raised its annual dividend from 30 to 33 yen, reflecting confidence in its financial outlook.
For further insights into JP:4527 stock, check out TipRanks’ Stock Analysis page.
